ORTHOFIX MEDICAL INC.

Recommendation history

• Q3 2025No clear callCautiously constructive, but not a clear post-call buy: Q3 revenue rose 6% to $203.4M, U.S. Spine Fixation grew 8% on 10% procedure growth, and adjusted EBITDA margin expanded 230 bps to 12.1%. The bull case is sustained distributor productivity, 7D adoption, and new products; the tension is that unchanged 2025 revenue guidance implies roughly 4% Q4 growth, while the larger VIRATA contribution is weighted to 2027 and Q4 free cash flow is expected to be below last year.
• Q2 2025No clear callVerdict: cautiously constructive, but not an aggressive buy after the call. Q2 pro forma revenue rose 4% to $200.7 million, adjusted EBITDA margin expanded 190 bps to 10.3%, and guidance was maintained at $808–$816 million revenue and $82–$86 million EBITDA. The bull case is accelerating U.S. Orthopedics, 7D adoption and distributor-led Spine recovery; the tension is that Spine growth remains price-discounted, distributor benefits are largely unquantified, and some margin improvement comes from discontinuing loss-making M6.
• Q1 2025No clear callVerdict: Hold/watch rather than buy immediately. Q1 was solid on reported operating execution—pro forma sales were $189.2 million, up 6% constant currency, while adjusted EBITDA was $11.4 million with roughly 200 bps of margin expansion—but the company cut 2025 revenue guidance to $808–$816 million while maintaining EBITDA guidance of $82–$86 million. The key tension is whether temporary Spine distributor disruption and a $5 million NGO headwind set up stronger growth, or mask more persistent commercial and pricing weakness.
• Q4 2024No clear callCautious buy: OFIX exited the $23.4 million M6 disc business, but Q4 execution was strong with $215.7 million of sales, 8% constant-currency growth, $23.9 million of adjusted EBITDA and $15.2 million of free cash flow. The 2025 guide calls for $818 million-$826 million of revenue, 6.5% constant-currency growth at the midpoint, and $82 million-$86 million of adjusted EBITDA, implying continued margin expansion; however, near-term results will be pressured by M6, FX, seasonal costs and weak Q1 cash flow, while the promised 7D pull-through remains insufficiently quantified.
• Q3 2024No clear callConstructive execution, but not yet a clear buy: Q3 revenue was $196.6 million, up 7% constant currency, adjusted EBITDA was $19.2 million with roughly 250 bps of margin expansion, and free cash flow turned positive at $5.9 million. The bull case is strong U.S. Spine Fixation growth (+18%), improving U.S. Orthopedics (+15%), and leverage from 7D and cross-selling; the tension is that the 2025–2027 plan only calls for 6%–7% sales CAGR and mid-teens adjusted EBITDA margin, while management offered no cash-conversion target and relies on execution, market growth, synergies, and gross-margin improvement.
• Q2 2024No clear callCautiously positive, but not an outright buy on this call: Q2 revenue rose 6% constant currency to $198.6 million, adjusted EBITDA increased 310 bps to an 8.4% margin, and FY2024 guidance was raised to $795–$800 million revenue and $64–$69 million EBITDA. The key upside is sustained share gains in US Spine Fixation (+12%) and BGT (+12%), alongside faster-than-expected cash generation; the tension is that management provided limited detail on sales-force expansion, 7D placements, and the durability of cross-selling, while longer-term EBITDA drop-through is expected to settle at only 30%–35%.
• Q4 2023No clear callWatch, but not an aggressive buy: Q4 revenue rose 6.9% to $200.4 million, adjusted EBITDA nearly doubled to $19.6 million, and BGT grew 15.3%, while U.S. spine fixation grew 13.5%. The 2024 outlook is deliberately conservative at $785–795 million revenue and $62–67 million EBITDA, with cash flow only expected to turn positive in Q4; the key tension is improving profitability versus substantial leverage and front-loaded cash use.